NextCure Stock
NextCure, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Michael S. Richman
- Employees
- 40
- Market cap
- $29 M
- IPO
- 09/05/2019
NextCure, Inc. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing innovative immunotherapies. Its core mission is to combat cancer and various other immune-related conditions by reactivating normal immune system function. The company's leading investigational compound, NC318, is…
NextCure stock: price history
1D
-9.3%
1W
-13.1%
1M
+3.5%
6M
-39.6%
YTD
-56.0%
1Y
-28.3%
2Y
-64.6%
5Y
-94.0%
10Y
–
Next earnings date
Next earnings date
04/11/2026 (in 18 days)
Volatility around earnings
~17% weaker price swings than usual
Ask the agents about NextCure
Analyst assessment of NextCure
PRICE TARGET LOW
US$20.00
CONSENSUS
US$20.00
MEDIAN
US$20.00
PRICE TARGET HIGH
US$20.00
0
STRONG BUY
11
BUY
1
HOLD
1
SELL
0
STRONG SELL
13
TOTAL · Buy
As of: 07/11/2025
NextCure stock metrics
P/E
-0.59
P/B
2.73
EV/EBITDA
-0.43
RETURN ON EQUITY
-122.6%
NET MARGIN
0.0%
DEBT/EQUITY
0.35
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
64.1%
FLOAT SHARES
2,934,133
AVG. DAILY VOLUME (30D)
92,323
Insider transactions (SEC)
Simcere Zaiming, Inc.
ADAR1 Capital Management, LLC
ADAR1 Capital Management, LLC
ADAR1 Capital Management, LLC
ADAR1 Capital Management, LLC
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about NextCure stock
What does NextCure do?
NextCure, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Michael S. Richman, the company employs around 40 people.
The IPO was on 09/05/2019; the stock trades on NASDAQ under the ticker NXTC.
What do analysts say about NextCure stock?
13 analysts rate the stock, the consensus is Buy (as of 07/11/2025).
The average price target is US$20.00, ranging from US$20.00 to US$20.00, with a median of US$20.00.
This is an external assessment, not a statement by Market Jury.
When does NextCure report next?
The next earnings date is 04/11/2026.
Around past earnings, price swings were roughly -17% stronger than usual.
Does NextCure pay a dividend?
No, NextCure currently does not pay a dividend.
Which stocks are comparable to NextCure?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get NextCure stock analyzed?
Clicking "Analyze stock" lets five strategies assess NextCure against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.